In this guide
What is Bitter Melon?
Bitter melon is Momordica charantia, a food and medicinal plant also called bitter gourd. Fresh fruit, juice, dried powder, tea and extracts can differ in species variety, ripeness, plant part and constituents. [1], [2], [5]
Typical Bitter Melon Protocols
| Source and question | Preparation | Amount each administration | Daily total | Frequency and duration | Main interpretation |
|---|---|---|---|---|---|
| Kim 2020 · double-blind RCT · 96 enrolled/90 analyzed | Bitter-melon extract versus placebo | 1,190 mg | 2,380 mg/day | Twice daily for 12 weeks | HbA1c remained unchanged; fasting glucose decreased within the extract group, while a clear between-group effect size was not reported in the abstract |
| Laczkó-Zöld 2023 · meta-analysis · 9 RCTs/414 participants | Momordica charantia products versus placebo | Varied by trial | Varied by trial | 4–16 weeks | No significant change-score effect for glucose, HbA1c, lipids, weight, BMI or blood pressure |
| Kim 2023 · prediabetes RCT · 76 randomized/65 analyzed | 70% ethanol extract of dried unripe bitter gourd | 800 mg across two tablets | 2,400 mg/day | Two tablets three times daily for 12 weeks | Prediabetes trial used a named extract; formulation-specific metabolic results do not establish a universal fruit dose |
- Exact product
- Record species, form, lot and co-ingredients.
- Each administration
- Keep amount, timing and context.
- Real endpoint
- Separate biomarker, symptom and clinical outcome.
What is it commonly used for?
A 2023 meta-analysis included nine randomized studies, 414 participants and 4–16 weeks and found no significant change-score benefit over placebo for fasting glucose, HbA1c, lipids, weight or blood pressure. One underlying double-blind trial enrolled 96 adults with type 2 diabetes and analyzed 90; bitter-melon extract 1,190 mg twice daily for 12 weeks left HbA1c unchanged, while fasting glucose decreased within the extract group. The abstract does not provide a clear between-group fasting-glucose effect size, so the result does not overturn the pooled null conclusion. [1], [2], [1], [2], [3]
One result answers one question
How do forms and labels differ?
Record M. charantia, fruit versus seed or mixed parts, fresh or dried preparation, extract ratio, amount per administration and co-ingredients. Juice volume and capsule milligrams cannot be converted without composition data. [4], [2], [5]
How should the product be stored?
Follow the finished product’s label, keep it dry in its original container and away from children. Discard an expired, heat-damaged, broken-seal or untraceable product.
What does human research show?
| Question | Best direct evidence | Finding | Boundary |
|---|---|---|---|
| Efficacy | Kim 2020 · double-blind RCT · 96 enrolled/90 analyzed | HbA1c remained unchanged; fasting glucose decreased within the extract group, while a clear between-group effect size was not reported in the abstract | Specific product and population |
| Replication | Limited evidence | No universal effect established | Variable formulations |
| Universal dose? | None | Not established | Rows cannot be combined |
Keep the finished product reviewable
What are the risks and interactions?
Bitter melon may add to glucose-lowering medicines. Seeds contain vicine-related compounds, creating a specific concern for people with G6PD deficiency or favism susceptibility. Pregnancy avoidance is prudent because of reproductive toxicity concerns; breastfeeding, children, liver or kidney disease and planned surgery require review. [2], [3], [5], [4], [5]
Seek urgent care for breathing difficulty, throat or tongue swelling, faintness, widespread hives, repeated vomiting or suspected overdose.
What is the legal and regulatory status?
In the United States, it is sold as a dietary supplement; FDA does not approve it for safety and effectiveness before sale. In Canada, verify the exact product, NPN and authorized label. Legal sale does not prove efficacy or sport suitability. [6]
When should use stop?
Stop for any allergic reaction, persistent symptom worsening, unexpected laboratory result or doubt about product identity.
What should be monitored?
Keep product, plant part, each amount, total, medicines, meals, activity, glucose and symptoms together. Track both low glucose and gastrointestinal symptoms. Do not interpret a single reading as efficacy.
What can community experience add?
Reports can compare bitterness, juice tolerance and readings. They cannot identify extract composition or overcome randomized null results. No systematic current community sample was assembled.
How do related options compare?
| Option | Main distinction |
|---|---|
| Fresh fruit or juice | Food matrix and variable constituent exposure |
| Dried powder | Plant part and ripeness still matter |
| Standardized extract | Specification applies only to that finished product |
Common questions
Did the current meta-analysis find lower HbA1c?
No significant advantage over placebo.
Were weight or cholesterol improved?
No significant pooled change-score effect.
Can the fruit replace diabetes medicine?
No.
Why does G6PD status matter?
Seed-related vicine exposure raises favism concern.
Is it appropriate in pregnancy?
Concentrated medicinal use should be avoided without specialist advice.
What should be recorded?
Plant part, form, dose, medicines, meals, glucose and symptoms.
Glossary
Terms for reading the evidence.
- Endpoint
- A defined result measured in a study.
- Anaphylaxis
- A potentially life-threatening systemic allergic reaction.
- Biomarker
- A biological measure that does not guarantee clinical benefit.
- Standardization
- A measured specification for a product component.
- Cross-reactivity
- Immune recognition of related proteins from different sources.
How this guide was researched
NCBI identities, publication notices, indexed abstracts and available open methods were checked. Null outcomes, mixed products, surrogate endpoints and missing details remain visible.
Research record · checked October 9, 2026
Identity: NCBI EFetch verified PMIDs 32951763, 37009042 and 38274207; PMC10050654 was read for the 70% ethanol extract, two-tablet administration and three-times-daily schedule. No linked correction or retraction appeared.
Outcome: the 2020 Kim trial's unchanged HbA1c and within-group fasting-glucose result remain distinct from a between-group treatment effect.
Synthesis: the current nine-trial change-score meta-analysis was null across reported metabolic outcomes.
Explore the sources
Primary human evidence and official context.
Showing 6 sources
- 01
Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus. ↗
Randomized double-blind placebo-controlled trial
Ninety-six enrolled and 90 analyzed; extract 1,190 mg twice daily for 12 weeks left HbA1c unchanged and produced a within-group fasting-glucose decrease.
- 02
Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study. ↗
Randomized double-blind placebo-controlled trial
Seventy-six randomized and 65 analyzed; a 70% ethanol extract of dried unripe fruit was given as two 400 mg tablets three times daily for 12 weeks.
- 03
The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials. ↗
Systematic review and meta-analysis of randomized trials
Nine studies, 414 participants and 4–16 weeks; no significant change-score benefit for the reported metabolic outcomes.
- 04
Diabetes and Dietary Supplements: What You Need To Know ↗
Official evidence and safety overview
Evidence for most diabetes supplements is limited; combining them with glucose-lowering treatment can cause unwanted effects.
- 05
Bitter Melon ↗
Official lactation evidence review
Summarizes limited human safety evidence and advises caution rather than assuming food use proves supplement safety.
- 06
FDA 101: Dietary Supplements ↗
Official supplement overview
FDA does not approve dietary supplements for safety and effectiveness before sale.
No matching sources
Try a different term or show the full list.
Editorial note
This guide separates composition, biomarker, symptom and clinical outcome. It does not turn a narrow signal into a general promise.